CCL19/MIP-3 beta Antibody (87102) [Alexa Fluor® 647]

• Reactivity: Mu
• Applications: WB, B/N, ELISA(Cap), ELISA(Det)
• Clone: 87102
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 647

CCL19/MIP-3 beta Antibody (87102) [Alexa Fluor® 647] Summary

• Immunogen: E. coli-derived recombinant mouse CCL19/MIP-3 beta
  Gly26-Val107-Leu-Glu (Ser108LeuGlu)
  Accession # Q548P0
• Specificity: Detects mouse CCL19/MIP‑3 beta in ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant human CCL1, 2, 3, 4, 5, 7, 8, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, recombinant mouse CCL1, 2, 3, 4, 5, 6, 7, 9
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair)
  • ELISA Detection (Matched Antibody Pair)
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL19/MIP-3 beta Antibody (87102) [Alexa Fluor® 647]

• beta chemokine exodus-3
• Beta-chemokine exodus-3
• CC chemokine ligand 19
• C-C motif chemokine 19
• CCL19
• chemokine (C-C motif) ligand 19
• CKb11
• EBI1-ligand chemokine
• ELC
• ELCMIP-3-beta
• Epstein-Barr virus-induced molecule 1 ligand chemokine
• exodus-3
• Macrophage inflammatory protein 3 beta
• macrophage inflammatory protein 3-beta
• MGC34433
• MIP3 beta
• MIP-3 beta
• MIP-3b
• MIP3BCK beta-11
• SCYA19EBI1 ligand chemokine
• small inducible cytokine subfamily A (Cys-Cys), member 19
• Small-inducible cytokine A19

Background

CCL19/MIP-3 beta , also known as ELC (EBI1-Ligand Chemokine), is a beta  chemokine that binds specifically to the chemokine receptor CCR7/EBI-1/BLR-2. Mouse (human) CCL19 cDNA encodes a 108 (98) amino acid precursor protein with a predicted 25 (21) aa signal peptide that is cleaved to form the 83 (77) aa mature secreted protein. CCL19 is distantly related to other beta chemokines (20 - 30% aa sequence identity). Mouse CCL19 shares 83% aa sequence homology with human CCL19. CCL19 has been shown to be constitutively expressed in various lymphoid tissues (including thymus, lymph nodes, appendix, and spleen) in dendritic cells within the T-cell zone. The expression of CCL19 is down-regulated by the anti-inflammatory cytokine IL-10. Recombinant CCL19 has been shown to be chemotactic for T-cells and B-cells. The CCL19 receptor (CCR-7/EBI-1/BLR-2) is expressed in various lymphoid tissues and activated B and T lymphocytes. CCR7 is also strongly up‑regulated in B-cells infected with Epstein-Barr virus and T-cells infected with herpesvirus 6 or 7.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q548P0()